Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 61.86M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 61.86M.
Fairly Valued
The company’s latest PE is -19.26, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 12.08M shares, increasing 18.49% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.67M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.37.